childrens-national-health-system-logo

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) is now accepting applications for its "Make Your Medical Device Pitch for Kids!" competition. The competition is focused on pediatric devices developed for use in the orthopedic and spine sector, an area of critical need which lacks innovation. Winning companies receive awards up to $50,000 and are invited to participate in the newly created NCC-PDI "Pediatric Device Innovator Accelerator Program" led by MedTech Innovator.

stem-cells-pixa

In November 2015, infectious disease epidemiologist Steffanie Strathdee and her husband, evolutionary psychologist Tom Patterson, were spending the week of Thanksgiving exploring pyramids and pharaoh’s tombs in Egypt when Patterson came down with what seemed like a nasty bout of food poisoning aboard their cruise ship. But as his condition rapidly deteriorated and he had to be emergency medevac’d, first to Germany and then to the medical center at UC San Diego, where both scientists were on staff, blood and imaging tests revealed why Patterson’s body was failing. A soccer-ball-sized cyst in his abdomen was infected—teeming with one of the most dangerous, antibiotic-resistant bacteria in the world.

roche-logo

The biotech sector has been a strong performer in 2019 after becoming quite oversold during the plunge in the high-beta parts of the market in the fourth quarter of 2018. Helping the sector recover and get off to a raucous start to the New Year were large buyouts of Celgene Corp(CELG) and Loxo Oncology Inc(LOXO) to start 2019, both with significan...

Antidote-Therapeutics-logo

Matt Kalnik wants to make smoking less addictive.

His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.

university-system-of-maryland-usm-2-logo

The Maryland Momentum Fund is a newly-created mechanism for investing in promising early stage companies associated with the University System of Maryland (USM). Maryland-based companies that are seeking equity financing or debt financing  that is convertible into equity may apply.  The funding provided by the Fund will normally be in the range of $150K-$250K, with a ceiling of $500K.  Recipients of this funding must obtain a matching investment (1:1) within six months, in either direction, from the date of commitment by the Fund.

Kauffman-Indicators-of-Entrepreneurship-logo

The Kauffman Indicators of Entrepreneurship offers in-depth measures, reports, and accompanying interactive data visualizations that present entrepreneurial trends in the United States.

blueberries-pixa

When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover.

umd-umgccc-logo

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is now certified to offer a groundbreaking treatment for non-Hodgkin lymphoma, in which a patient’s own immune cells are genetically engineered to recognize and attack the cancer.

autm-2019-logo

To spare you all a power point presentation, I thought I’d share some thoughts today about how and why our tech transfer system was created and the importance of practitioners continually developing best practices to maintain it.

Woody Allen said that half of life is showing up. Perhaps the other half is working with people who give you the opportunity to show what you can do.

bhi updated logo 2017

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan?  Sign up by noon 3/26 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more, next Wednesday, February 27th.  (Future sessions scheduled for 3/20 and 5/22.)  Pre-registration is required; sign up here ("EIR resource" at BHI).  For questions/more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it..

bhi launch tedco mont county logo

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW:  https://tinyurl.com/BHISBIR2019

  • 8:00 a.m. – Networking and Registration
  • 8:30 a.m. – Welcome
  • 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
    • National Heart, Lung, and Blood Institute
    • National Institute on Aging
    • National Institute on Drug Abuse
    • National Cancer Institute  
  • 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab  
  • 10:00 a.m. – BREAK
  • 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation    
  • 11:00 a.m. – BREAK  
  • 11:15 a.m. – SBIR Funding Opportunities with USAMRC    
  • 11:45 a.m. –  Lunch  
  • 12:45 p.m. – (1:1 Room Set)  
  • 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)  
  • 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 2:30 p.m. –  Writing Your Phase II Commercialization Plan  OR 1:1 Meetings* (available simultaneously))  
  • 3:00 p.m. –  1:1 Meetings* (NIH only)  
  • 4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019
No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.

schulz-md-image

Kelly M. Schulz, the newly appointed state secretary of commerce, could be called the secretary of opportunity. Her vision for the state of Maryland is for economic development, job growth, full employment and economic prosperity for all families around the state.

nation-foundation-for-cancer-research-nfcr-logo

The National Foundation for Cancer Research (NFCR) announced today that Steven A. Rosenberg, M.D., Ph.D., of the U.S. National Cancer Institute (NCI) has been selected to receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The Prize selection committee awarded Dr. Rosenberg for not only revolutionizing—if not originating—the field now known as cancer immunotherapy but also remaining at its forefront. Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda since 1974, his basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of drugs such as Chiron’s (later Novartis and Prometheus Labs’) Proleukin, Bristol-Myers Squibb’s Yervoy and Gilead’s Yescarta.

america-gene-technologies-logo

American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.

biotalk-andres-article-image.jpg

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Listen now on iTunes Google Play , and TuneIn

sr-one-logo

At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science. 

himss-logo

Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.